drugset / Trial / NCT00411697

Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B Vaccine Challenge

NCT00411697 ↗

Phase 4 Completed 301 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine at 5 years of age the persistence of immunity to hepatitis B that was conferred by infant vaccination with Infanrix hexa™. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Timeline

Start
2006-12
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Engerix™-B Kinder Vaccine — Intramuscular